Ocular Therapeutix (OCUL) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $13.0 million.
- Ocular Therapeutix's Cost of Revenue rose 1952.95% to $13.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $53.9 million, marking a year-over-year increase of 2965.14%. This contributed to the annual value of $53.9 million for FY2025, which is 2965.14% up from last year.
- Ocular Therapeutix's Cost of Revenue amounted to $13.0 million in Q4 2025, which was up 1952.95% from $13.1 million recorded in Q3 2025.
- In the past 5 years, Ocular Therapeutix's Cost of Revenue registered a high of $14.1 million during Q1 2025, and its lowest value of $8.1 million during Q1 2021.
- Its 5-year average for Cost of Revenue is $10.6 million, with a median of $10.2 million in 2022.
- In the last 5 years, Ocular Therapeutix's Cost of Revenue surged by 4687.12% in 2021 and then crashed by 1221.99% in 2023.
- Over the past 5 years, Ocular Therapeutix's Cost of Revenue (Quarter) stood at $9.1 million in 2021, then increased by 15.28% to $10.5 million in 2022, then dropped by 12.22% to $9.2 million in 2023, then increased by 17.25% to $10.8 million in 2024, then rose by 19.53% to $13.0 million in 2025.
- Its Cost of Revenue was $13.0 million in Q4 2025, compared to $13.1 million in Q3 2025 and $13.7 million in Q2 2025.